옵션 체인은 다양한 행사가격과 만기일에 대한 89bio의 주식 옵션 주요 데이터를 보여줍니다. 트레이더들은 이 정보를 사용하여 잠재적 거래를 분석하고 89bio에 대한 시장 심리를 평가합니다..

89bio (NASDAQ:ETNB) 주식, 옵션 체인

89BIO INC

89bio

89bio Inc is a United States-based clinical-stage biopharmaceutical company focused on the development and commercialization of therapies for the treatment of liver and cardio-metabolic diseases. Its product candidate, pegozafermin (previously BIO89-100), a specifically engineered glycoPEGylated analog of fibroblast growth factor 21 (FGF21), is currently being developed for the treatment of nonalcoholic steatohepatitis (NASH) and for the treatment of severe hypertriglyceridemia (SHTG).

89bio Inc

Effective June 2, 2025, Ernexa Therapeutics Inc. (the "Company"), filed a certificate of amendment to the Company's Restated Certificate of Incorporation, as amended (the "Amended COI") with the Secretary of State of Delaware to increase the authorized shares of its common stock from 100,000,000 to 150,000,000.
&nbsp;
Additionally, effectively June 2, 2025, the Company filed a certificate of amendment to its Amended COI with the Secretary of State of Delaware to allow for action required or permitted to be taken by stockholders of the Company to be effected by written consent of such stockholders in addition to duly called annual or special meetings of such stockholders.

News

ERNA

Reported Earlier: Ernexa Therapeutics Amends Certificate Of Incorporation To Increase Authorized Common Stock From 100M To 150M Shares

New long-term CARTITUDE-1 data show one-third of patients treated with CARVYKTI&#xAE;&nbsp;remain progression-free
CARTITUDE-4 analysis shows compelling overall survival and progression-free benefits in standard and high-risk subgroups across prior lines of treatment
CHICAGO, June 3, 2025 /PRNewswire/ --&nbsp;Johnson &amp; Johnson (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/JNJ#NYSE">JNJ</a>) announced today new long-term follow-up data from the Phase 1b/2 CARTITUDE-1 study demonstrating 33 percent (n=32) of patients in the study (n=97) with relapsed or refractory multiple myeloma (RRMM) treated with CARVYKTI&#xAE; (ciltacabtagene autoleucel; cilta-cel) achieved progression-free survival (PFS) of five years or more with a single infusion and no maintenance or subsequent anti-myeloma therapy.1 These data underscore Johnson &amp; Johnson's dedication to advancing transformative therapies that aim to reshape the treatment landscape for patients with multiple myeloma.
In a subset of 12 patients who underwent serial evaluations at a single site, all were minimal residual disease (MRD) negative and imaging negative throughout five years of post-treatment follow-up. Findings were featured in an oral presentation at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting (Abstract #7507). The data were also simultaneously published in The Journal of Clinical Oncology.

Johnson & Johnson Says New Long-Term CARTITUDE-1 Data Show One-Third Of Patients Treated With CARVYKTI Remain Progression-Free

Stifel analyst Tore Svanberg maintains Credo Technology Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CRDO#NASDAQ">CRDO</a>) with a Buy and raises the price target from $69 to $80.

Price Target

Analyst Ratings

CRDO

Stifel Maintains Buy on Credo Technology Group, Raises Price Target to $80

Telsey Advisory Group analyst Dana Telsey maintains Designer Brands (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DBI#NYSE">DBI</a>) with a Market Perform and maintains $5 price target.

Telsey Advisory Group Maintains Market Perform on Designer Brands, Maintains $5 Price Target

More than half of patients maintained minimal residual disease (MRD) negativity (10-5) with DARZALEX FASPRO&#xAE;&nbsp;for 24 months or longer in the Phase 3 PERSEUS study
Data from Phase 3 CEPHEUS study show 60 percent overall MRD negativity (10−5) and improved PFS with DARZALEX FASPRO&#xAE; in transplant-ineligible newly diagnosed patients
CHICAGO, June 3, 2025 /PRNewswire/ -- Johnson &amp; Johnson (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/JNJ#NYSE">JNJ</a>) today announced data from two studies highlighting that a DARZALEX FASPRO&#xAE; (daratumumab and hyaluronidase-fihj)-based quadruplet regimen demonstrated deep and sustained minimal residual disease (MRD) negativity rates, and improved long-term progression-free survival (PFS) in patients with newly diagnosed multiple myeloma (NDMM), regardless of transplant status.1,2,3 Findings were highlighted as oral presentations of an analysis of sustained MRD in transplant-eligible patients from the Phase 3 PERSEUS study (Abstract #7501) and a subgroup analysis of transplant-ineligible patients in the Phase 3 CEPHEUS study (Abstract #7516) at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting.

Johnson & Johnson Announces Data From Two Studies Highlighting That DARZALEX FASPRO-Based Quadruplet Regimen Demonstrated Deep And Sustained MRD Negativity Rates, And Improved Long-Term PFS In NDMM Patients

Rumors

Trading Ideas

CURI

Watching CuriosityStream; Traders Circulate Zacks Under $10 Newsletter Picks Stock

VUZI

Wyr.ai Partners With Vuzix On Launch Of M400 Smart Glasses-Based AI Quality Assurance Inspection Platform; Terms Not Disclosed

D. Boral Capital analyst Jason Kolbert maintains Estrella Immunopharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ESLA#NASDAQ">ESLA</a>) with a Buy and maintains $16 price target.

ESLA

D. Boral Capital Maintains Buy on Estrella Immunopharma, Maintains $16 Price Target

Phase 1 trial demonstrates encouraging clinical activity of investigational&nbsp;immunotherapy for relapsed or refractory multiple myeloma
Novel investigational dual-antigen-targeting&nbsp;immunotherapy binds to B-cell maturation antigen (BCMA) and GPRC5D on myeloma cells, as well as CD3 on T-cells&nbsp;
CHICAGO, June 3, 2025 /PRNewswire/ -- Johnson &amp; Johnson announced today initial Phase 1 results of JNJ-79635322 (JNJ-5322), a novel investigational trispecific antibody (TsAb) in patients with relapsed or refractory multiple myeloma. Among the 36 patients who received the recommended phase 2 dose (RP2D), the overall response rate (ORR) was 86.1 percent. In the 27 patients who were naive to BCMA and GPRC5D directed therapies, the ORR was 100 percent at the RP2D. Findings were featured in an oral presentation at the <a href="https://c212.net/c/link/?t=0&amp;l=en&amp;o=4439656-1&amp;h=1437573614&amp;u=https%3A%2F%2Fmeetings.asco.org%2Fmeetings%2F2025-asco-annual-%2520meeting%2F327%2Fprogram-guide%2Fscheduled-sessions&amp;a=2025+American+Society+of+Clinical+Oncology+(ASCO)+Annual+Meeting">2025 American Society of Clinical Oncology (ASCO) Annual Meeting</a> (Abstract #<a href="https://c212.net/c/link/?t=0&amp;l=en&amp;o=4439656-1&amp;h=2239716214&amp;u=https%3A%2F%2Fwww.asco.org%2Fabstracts-presentations%2FABSTRACT489908&amp;a=7505">7505</a>). The study will also be featured as one of the six best abstracts during the Plenary Abstracts Session at the <a href="https://c212.net/c/link/?t=0&amp;l=en&amp;o=4439656-1&amp;h=2405979170&amp;u=https%3A%2F%2Fehaweb.org%2Fcongress%2Feha2025-congress%2F&amp;a=2025+European+Hematology+Association+(EHA)+Congress">2025 European Hematology Association (EHA) Congress</a> (Abstract #<a href="https://c212.net/c/link/?t=0&amp;l=en&amp;o=4439656-1&amp;h=3428041764&amp;u=https%3A%2F%2Flibrary.ehaweb.org%2Feha%2F2025%2Feha2025-congress%2F4159177%2Frakesh.popat.first-in-human.study.of.jnj-79635322.28jnj-532229.a.novel.html%3Ff%3Dmenu%253D6%252Abrowseby%253D8%252Asortby%253D2%252Amedia%253D3%252Ace_id%253D2882%252Amarker%253D5848%252Afeatured%253D19595&amp;a=S100">S100</a>).

Johnson & Johnson Announces Initial Phase 1 Results Of JNJ-79635322, Investigational TsAb In Patients With Relapsed Or Refractory Multiple Myeloma

WIIM

ENTA

Enanta Pharmaceuticals shares are trading higher after JMP Securities maintained an Outperform rating on the stock and raised its price target from $23 to $24.

A 22-year-old college student called into &#8220;<a href="https://www.youtube.com/watch?v=3Sg4BQWIYyo">The Ramsey Show</a>&#8221; and said he was being financially &#8220;abused&#8221; by his parents. The student, identified only as Tyler, said he had been following Dave Ramsey&#8216;s <a href="http://www.benzinga.com/personal-finance/25/05/45680116/couple-making-200k-wants-to-invest-60-of-their-income-dave-ramsey-says-thats-great-but-build-up-a-fat-juicy-down-payment-for-a-house-instead">baby steps</a> and recently used a school refund to pay off debt. His parents were not happy about it.
<h2 class="wp-block-heading">Student Loan Refund Sparks Family Drama</h2>
&#8220;I got my refund from school in May and it was close to about $4,000—exactly $3,999,&#8221; Tyler told hosts Jade Warshaw and Ken Coleman. &#8220;I used that money to pay off my debt, my car payment, and a little bit of my credit card payment.&#8221;
Don't Miss:
<ul class="wp-block-list">
<li>Maximize saving for your retirement and cut down on taxes: <a href="https://www.benzinga.com/money/wideradvisor-retirement-planning">Schedule your free call with a financial advisor to start your financial journey – no cost, no obligation</a>. </li>
<li>Invest where it hurts — and help millions heal:<a href="https://www.benzinga.com/money/a-cure-for-osteoarthritis-powered-by-everyday-investors-cytonics-is-looking-to-beat-big-pharma-and-disrupt-a-390-billion-market"> Invest in Cytonics and help disrupt a $390B Big Pharma stronghold</a>.</li>
</ul>
Tyler said his parents were furious, claiming the money was theirs. &#8220;They were just absolutely furious about me, saying that that was their money and about the hard work they did to put me out here,&#8221; he explained.
He summed up the situation in one sentence: &#8220;My parents are financially abusing me.&#8221;
Coleman asked for clarification: was the refund from money Tyler had earned through work, or was it part of a student loan? Tyler said it was a mix of both—federal work-study and student loan overage.
When asked whose name was on the loan, Tyler replied, &#8220;I believe it&#8217;s mom and then me. I believe I&#8217;m the co-signer on it.&#8221;
That raised a red flag for the hosts. &#8220;You should have communicated with the parents because they&#8217;re involved in this financially,&#8221; Coleman told him..
Warshaw agreed, saying that while <a href="https://www.benzinga.com/money/how-to-pay-off-debt">paying off debt</a> was a smart instinct, Tyler should have talked to his mom first. &#8220;If your mom was like, &#8216;Wait a minute, you took this loan money that we&#8217;re both on the hook for to do this thing without consulting both of us,&#8217; I can see that,&#8221; she said.
Trending: <a href="https://www.benzinga.com/money/this-ai-imaging-technology-has-been-used-in-more-than-500-surgeries-now-you-can-be-part-of-the-ai-imaging-revolution">Be part of the next med-tech breakthrough for only $350 — 500+ surgeries already done with nView's AI system.</a>
<h2 class="wp-block-heading">Is It Really Abuse?</h2>
Tyler accused his parents of financially abusing him, but both hosts pushed back on the use of that word.
&#8220;I see no evidence of that,&#8221; Warshaw said bluntly. &#8220;You&#8217;re 22 now. Your parents can make suggestions, they can even try to strong-arm you to do things their way, but you don&#8217;t have to.&#8221;
Coleman was more direct: &#8220;You need to stop saying they&#8217;re financially abusing you because this is not anywhere close to it. It&#8217;s dramatic, and by the way, words matter.&#8221;
Tyler claimed the tension comes from his parents&#8217; spending habits. &#8220;They&#8217;re both spenders&#8230; My mom just bought a brand new Mercedes. My dad spends money constantly on his new truck,&#8221; he said. &#8220;They&#8217;ve always been haggling me for money.&#8221;
He also said they pressured him to help pay for a down payment on a truck—something he didn't want to do. Warshaw responded, &#8220;Then you don&#8217;t have to do it.&#8221;
See Also: The average American couple has saved this much money for retirement —<a href="http://www.benzinga.com/money/smartasset"> How do you compare</a>?
<h2 class="wp-block-heading">Future Debt Could Tie Him To Parents Even More</h2>
The conversation shifted toward Tyler&#8217;s financial future. He currently has $40,000 in student loans and expects it to reach around $80,000 after finishing his degree in sports management at the University of Tennessee.
&#8220;You&#8217;re following in [your parents&#8217;] footsteps right now because you are taking on debt and you&#8217;re <a href="https://www.benzinga.com/personal-finance/24/11/41914082/dave-ramsey-says-its-stupid-to-go-into-debt-for-a-career-you-dont-borrow-money-to-cross-state-lines">going to an out-of-state school</a>,&#8221; Warshaw said. She advised Tyler to consider in-state options or work his way through school without borrowing more money, especially since his mother is on the loans.
&#8220;Mama&#8217;s going to be breathing down your neck every month, talking about, &#8216;Where&#8217;s the payment? You&#8217;re messing up my credit,'&#8221; she warned. &#8220;And that is going to jack you and her.&#8221;
Coleman added, &#8220;Nobody cares where you get your degree from. There&#8217;s a better way, Tyler.&#8221;
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/money/gbr-savings-by-age">If You're Age 35, 50, or 60: Here&#8217;s How Much You Should Have Saved Vs. Invested By Now</a></li>
<li>Many are using retirement income calculators to check if they&#8217;re on pace —<a href="https://www.benzinga.com/money/how-do-i-calculate-my-retirement-income-adv"> here&#8217;s a breakdown on what&#8217;s behind this formula.</a></li>
</ul>
Image: Shutterstock

Personal Finance

'My Parents Are Financially Abusing Me'—A College Kid Used His $3,999 School Refund To Pay Off Debt, But His Parents Say It Belongs To Them

Michael Saylor's Strategy (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MSTR#NASDAQ">MSTR</a>), the world's largest corporate holder of Bitcoin (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/btc/usd">BTC</a>) on Monday introduced a new preferred stock product: Series A Stride Preferred (STRD) is designed to provide a <a href="https://www.benzinga.com/crypto/25/06/45718471/michael-saylors-strategy-outperforms-apple-tesla-amazon-and-other-mag-7-stocks-and-its-not-even-close-has-the-bitcoin-treasury-bet-paid-off">high-yield return for long-term investors.</a>
The STRD <a href="https://x.com/saylor/status/1929871463521136697">offering</a> marks the company's third preferred instrument as it continues building a structured and diversified capital stack anchored in Bitcoin exposure.
STRD delivers a fixed 10% dividend with perpetual duration and ranks below Strategy's senior preferred instrument (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/STRF#NASDAQ">STRF</a>), but above the firm's common equity.
It is structured to sit at the riskier end of the firm's yield curve but compensates investors with its highest payout to date among Strategy's preferred options.
Unlike (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/STRF#NASDAQ">STRF</a>), which prioritizes capital preservation and mimics the risk profile of investment-grade fixed income, STRD is intended for investors seeking higher returns despite increased subordination.
Meanwhile, Strategy's other product STRK (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/STRK#NASDAQ">STRK</a>) offers an 8% dividend and the added benefit of convertibility, placing it squarely between STRF and STRD in terms of both yield and risk.
Strategy's common stock MSTR remains the base layer of its capital stack, functioning as the firm's core vehicle for leveraged Bitcoin exposure.
The STRD issuance is non-callable in typical market conditions, though it may be repurchased if certain events occur, such as a major corporate restructuring or tax-related change. 
Also Read: <a href="https://www.benzinga.com/crypto/cryptocurrency/25/06/45744569/michael-saylors-strategy-to-outperform-bitcoin-heres-how-it-could-happen">Michael Saylor&#8217;s Strategy To Outperform Bitcoin? Here&#8217;s How It Could Happen</a>
Dividends will be distributed quarterly, in cash, but only at the discretion of the board.
The firm claims STRD compares favorably to other high-yield investment vehicles on the market. 
For example, unlike ETFs such as iShares Preferred &amp; Income Securities ETF (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PFF#NASDAQ">PFF</a>) and iShares Broad USD High Yield Corporate Bond ETF (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/USHY#NASDAQ">USHY</a>), STRD carries no management fees and offers a stronger yield proposition: 10% versus 7–8% for its ETF counterparts, while maintaining comparable volatility.
This new product aligns with Strategy's broader push to merge structured financial instruments with crypto exposure. 
The goal: deliver yield, diversification and exposure to digital assets in formats that fit traditional investment portfolios.
According to the company, the launch of STRD further extends its commitment to modernizing capital formation strategies using a layered and yield-tiered approach rooted in both crypto conviction and financial discipline.
Read Next: 
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/markets/25/06/45741645/ethereum-books-record-institutional-inflows-xrp-sees-outflows-what-is-going-on">Ethereum Books Record Institutional Inflows, XRP Sees Outflows: What Is Going On?</a></li>
</ul>
Image: Shutterstock

Coverage of Bitcoin, Etherum, Ripple and all the latest digital currencies.

Cryptocurrency

$BTC

MSTR

iShares S&P US Preferred Stock Index Fund

STRF

STRK

USHY

Strategy Launches STRD Preferred Stock Offering 10% Yield

<ul>
<li>Oral presentation of CARTITUDE-1 study data showcases long-term outcomes after a single infusion of CARVYKTI&#xAE; with one-third of patients with relapsed/refractory multiple myeloma progression-free for ≥5 years</li>
<li>CARTITUDE-4 subgroup analyses featured in a poster presentation highlight consistent, durable progression-free and overall survival benefit vs. standard therapies across cytogenetic risk groups as early as second-line therapy</li>
<li>Promising early results from ongoing Phase 1 dose-escalation studies of LB1908 in gastroesophageal cancers and LB2102 in lung cancers underscore potential of next-generation cell therapies &nbsp;</li>
</ul>
SOMERSET, N.J., June 03, 2025 (GLOBE NEWSWIRE) -- Legend Biotech Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LEGN#NASDAQ">LEGN</a>) (Legend Biotech), a global leader in cell therapy, announced today new long-term results from the CARTITUDE-1 study in heavily pretreated relapsed/refractory multiple myeloma (RRMM) patients. RRMM patients were treated with a single infusion of CARVYKTI&#xAE; (ciltacabtagene autoleucel; cilta-cel) with no maintenance or subsequent myeloma therapy. Notably, an unprecedented 33% (32 of 97) of patients remained progression-free for five years or more.
These data were featured in an oral presentation at the 2025&nbsp;American Society of Clinical Oncology&nbsp;(ASCO) Annual Meeting (<a href="https://www.globenewswire.com/Tracker?data=SUvaU_r4L_ZQGCtcGNJFmwrN7awYRxvTJx-N64piM7dYeIDzCpoh6j_mHdFQX52t67C83Czvmcia9-49Nw4jEJkkqeoBXxtLV3aq3F2REjHx5e2-DGfM4zrlCFa_8zyYtNWxf7rSBbYfxybbPj60vg==">Abstract #7505</a>). To date, more than 6,500 patients have been treated with CARVYKTI&#xAE;, the first and only CAR T-cell treatment in multiple myeloma to show overall survival benefit vs. standard of care.
In a subset of 12 patients from a single center from this analysis who underwent serial minimal residual disease (MRD) assessments, all 12 patients remained progression-free ≥5 years, were MRD-negative and showed no disease on annual PET/CT scans for five years.

LEGN

Legend Biotech Announces New Long-Term Results From CARTITUDE-1 Study In Heavily Pretreated Relapsed/Refractory Multiple Myeloma Patients

ALTG

Alta Equipment Group shares are trading higher after the company disclosed in a Form4 filing that the director, Andrew Studdert, accuired approximately 10,000 shares at an average price of $4.80 per share.

Encompass Health (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EHC#NYSE">EHC</a>) has outperformed the market over the past 10 years by 2.27% on an annualized basis producing an average annual return of 13.3%. Currently, Encompass Health has a market capitalization of $12.19 billion. 
Buying $100 In EHC: If an investor had bought $100 of EHC stock 10 years ago, it would be worth $347.85 today based on a price of $120.85 for EHC at the time of writing.
<h3>Encompass Health's Performance Over Last 10 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1748961912_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Here's How Much $100 Invested In Encompass Health 10 Years Ago Would Be Worth Today

WeRide (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WRD#NASDAQ">WRD</a>), a leading global developer of <a target="_blank" href="https://www.benzinga.com/pressreleases/25/06/g45741282/weride-teams-up-with-renault-to-bring-autonomous-shuttle-to-roland-garros-again" rel="noreferrer noopener">autonomous driving technology</a>, announced on Tuesday it will once again partner with Renault Group, a key Roland-Garros sponsor, to provide a Level-4 self-driving minibus shuttle during the 2025 Grand Slam tennis tournament in Paris.
The return of the Robobus service highlights the successful partnership between the two companies. After a dependable debut last year, the shuttle will run a 2.8-kilometer loop connecting key venues around Roland-Garros daily from May 25 to June 8.
A new addition for this year is a night schedule, operational from 10 p.m. to midnight, thereby enhancing access during periods of low light.
Also Read: <a target="_blank" href="https://www.benzinga.com/markets/large-cap/25/06/45742446/toyota-restructures-complex-shareholding-pattern-in-mobility-push" rel="noreferrer noopener">Toyota Restructures Complex Shareholding Pattern In Mobility Push</a>
Tony Han, WeRide&#8217;s founder and CEO, emphasized the importance of their continued presence at Roland-Garros and their focus on expanding in Europe.
Patrick Vergelas, Autonomous Mobility Project Manager at Renault Group, highlighted the growing societal acceptance of autonomous transit. &#8220;From Roland-Garros to Barcelona, via Valence, Renault and WeRide demonstrate that autonomous mobility is no longer a promise, but a reality,&#8221; he stated.
This initiative follows WeRide and Renault&#8217;s launch in March 2025 of Europe&#8217;s first fully driverless commercial <a target="_blank" href="https://www.benzinga.com/markets/equities/25/02/44041348/werides-robobus-rolls-out-in-france-with-renault-beti-backing-details" rel="noreferrer noopener">Robobus</a> in France&#8217;s Drôme region and a Level-4 autonomous shuttle trial in Barcelona. Powered by WeRide&#8217;s proprietary system, the Robobus operates in nearly 30 cities worldwide, including Singapore, Switzerland, France, and China.
WeRide reported <a target="_blank" href="https://www.benzinga.com/cannabis/25/05/45541961/whats-going-on-with-weride-stock-on-wednesday" rel="noreferrer noopener">$10 million in revenue</a> for the first quarter of 2025, a 1.8% increase year-over-year. Product sales, including robotaxis and robosweepers, rose to $1.3 million. The robotaxi segment grew to 22.3% of total revenue. Gross margin remained steady at 35%.
ETFs such as the Global X Autonomous &amp; Electric Vehicles ETF (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DRIV#NASDAQ">DRIV</a>) and the iShares Self-Driving EV and Tech ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IDRV#NYSE">IDRV</a>) also provide exposure to this emerging market.
Price Action: WRD shares are trading lower by 2.55% to $9.55 at last check Tuesday.
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/news/health-care/25/06/45743008/mercks-dealmaking-intensifies-with-moonlake-bid-as-keytruda-patent-cliff-nears-report" target="_blank" rel="noreferrer noopener">Merck&#8217;s Dealmaking Intensifies With MoonLake Bid As Keytruda Patent Cliff Nears: Report</a></li>
</ul>
Photo by Tada Images via Shutterstock

Movers

Tech

DRIV

IDRV

WeRide, Renault Bring Autonomous Shuttles Back To Roland-Garros In Paris

Truist Securities analyst Michael Swartz maintains Winnebago Industries (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WGO#NYSE">WGO</a>) with a Buy and raises the price target from $38 to $40.

Truist Securities Maintains Buy on Winnebago Industries, Raises Price Target to $40

DA Davidson analyst Linda Bolton Weiser maintains Natures Sunshine Products (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NATR#NASDAQ">NATR</a>) with a Buy and maintains $19 price target.

NATR

DA Davidson Maintains Buy on Natures Sunshine Products, Maintains $19 Price Target

Truist Securities analyst Michael Lewis maintains Vornado Realty (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VNO#NYSE">VNO</a>) with a Hold and raises the price target from $37 to $38.

Truist Securities Maintains Hold on Vornado Realty, Raises Price Target to $38

Stephens &amp; Co. analyst Terry McEvoy reiterates Regions Finl (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RF#NYSE">RF</a>) with a Overweight and maintains $24 price target.

Comments

89bio

89bio (ETNB) 옵션

89bio (NASDAQ:ETNB) 주식, 옵션 체인

뉴스

파트너 / 기고자

벤징가 글로벌